A prospective randomized study on the mobilization of CD34+ cells comparing continuous intravenous vs subcutaneous administration of rhG-CSF in normal donors.
The efficacy of mobilizing peripheral blood progenitor cells (PBPC) with continuous intravenous (c.i.v.) administration of rhG-CSF was randomly compared to subcutaneous (s.c.) administration, in 15 normal donors in each arm of the study for 6 days. The percentage and absolute numbers of CD34+ cells in the c.i.v. and s.c. groups increased maximally at day 3 and 5, respectively, when compared with the steady-state (day 0) level. Peak CD34+ cell levels were achieved on day 3 in the c.i.v. group, with more rapid results than in the s.c. group (49.3/microl vs 35.9/microl, P=0.043). Plasma rhG-CSF levels declined progressively during mobilization in each group as the WBC increased. The serum level of rhG-CSF did not correlate with CD34+ cell counts in the peripheral blood. Toxicity profiles in the c.i.v. and s.c. groups were similar. Each regimen was effective in successfully mobilizing the target CD34 cell number.
Lee
K-E
KE
Department of Hematology-Oncology, Ewha Women's University, Seoul, Republic of Korea.
Mun
Y C
YC
Nam
S-H
SH
Kwon
J M
JM
Lee
S M
SM
Lee
M-A
MA
Yoo
E-S
ES
Ahn
J-Y
JY
Kim
J-H
JH
Seong
C-M
CM
D000293:Adolescent; D000328:Adult; D018952:Antigens, CD34 / Q000096:biosynthesis*; D002469:Cell Separation; D005260:Female; D005434:Flow Cytometry; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006801:Humans; D016130:Immunophenotyping; D007262:Infusions, Intravenous / Q000379:methods*; D007279:Injections, Subcutaneous / Q000379:methods*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D010641:Phenotype; D011446:Prospective Studies; D011994:Recombinant Proteins; D013997:Time Factors
D018952:Antigens, CD34; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor